22 RESULTS
Go to another page:
COMMENT The announcement by the FDA of their Final Rule for increased oversight of laboratory developed tests (LDTs) is long overdue but very welcome. Once fully implemented, this should greatly increase the scientific rigor required for certifying LDTs for clini
COMMENT Agree that it is no longer correct to assume that white matter rarefaction is equivalent to or completely accounted for by small vessel disease. Our comprehensive postmortem study suggests that neuofibrillary tangles are statistically a much greater predi
COMMENT The publication of Gibbons et al., like most clinical biomarker studies, suffers first and foremost from the use of an inadequate gold standard. The clinical diagnoses of Parkinson’s disease, dementia with Lewy bodies, and multiple system atrophy are all
COMMENT This report is intriguing and reinforces the power of single-nucleus studies of human postmortem brain tissue for understanding neurodegenerative disease. The identification of RORB as a possibly critical protein associated with selective vulnerability ma
COMMENT Readers should see comments made earlier this year on the same topic, i.e., my own comment
COMMENT Multicenter studies with enforced blinding of results assessment will be necessary to resolve the discrepancies in reports from different labs. As mentioned in this paper, a very well respected Johns Hopkins group (Ho et al., 2013) found no evidence for e
COMMENT The sensitivity and specificity of tau tracers for human tau pathology cannot be known until there have been a substantial number of imaged patients with autopsies and neuropathological diagnoses. Clinical diagnostic accuracy for non-Alzheimer's deme
COMMENT This is an impressive result, agreed. Just would like to point out that the most likely and earliest entry point for an exogenous process would be through the olfactory bulb, not the gut. Our thorough survey of the peripheral nervous system in subjects wi
COMMENT I think the results raise several questions and have some implications for the disease in humans, but I think it is also exciting that some of the implications and hypotheses arising from the finding can be tested in the transgenic mouse model used. For h
COMMENT I would note that since the overall prevalence of melanoma in Parkinson's disease (PD) is pretty low, it is difficult to see a large role for melanoma-related mechanisms in PD, or vice versa. Also, the extra medical attention that a subject gets afte
COMMENT Interesting paper and nice to see some experimental work being done in this area. I would like to refer readers in this field to our recent papers (below), which confirm earlier work by several investigators that olfactory bulb is universally affected in
COMMENT This paper describes a new staging system for all Lewy body disorders and has been badly needed as the two prior major staging systems have failed to classify 40-60 percent of cases. The major differences from prior staging methods are that the rules for
COMMENT Tubingen conference. Many thanks to Andre Delacourte for his comments and his posted translation of Blocq
COMMENT This interesting study suggests a molecular mechanism that may explain how CAA contributes to dementia. Clinical studies have indicated that CAA contributes to the dementia in AD, and it has been apparent for decades that CAA eventually results in vascula
COMMENT The paper by LaFerla and colleagues adds to considerable evidence suggesting that M1 receptor activation leads to decreased amyloidogenic processing of APP while reduced M1 receptor activation, by means of either pharmacological agents or cholinergic lesi
Go to another page:
